Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
about
Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector.The Cell Surface Markers Expression in Postmenopausal Women and Relation to Obesity and Bone Status.Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.
P2860
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@en
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@nl
type
label
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@en
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@nl
prefLabel
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@en
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@nl
P2093
P2860
P1433
P1476
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.
@en
P2093
Anna Cline-Smith
Deborah V Novack
Elena Shashkova
Jesse Gibbs
Zachary S Buchwald
P2860
P356
10.1172/JCI.INSIGHT.88839
P577
2016-08-01T00:00:00Z